Optimizing LDL-C Management with PCSK9 Inhibitors: The Potential of an Oral Alternative and Addressing Medication Compliance for Improved Cardiovascular Outcomes

Público Deposited

Conteúdo disponível para baixar

4m90dw03k?file=thumbnail
Read Download

Item Description

Description
  • A meta-analysis comparing injectable and oral PCSK9i therapies, including the emerging oral agent MK-0616, found comparable LDL-C reductions across all drug classes. Notably, oral formulation may improve treatment adherence due to needle aversion, which affects a significant portion of patients. These findings highlight the potential of oral PCSK9 inhibitors to close the treatment gap in ASCVD management and support more patient-friendly approaches to lipid-lowering therapy.
Date created
Creator
Orcid
  • 0009-0003-9891-7350
Subject
Mentor
Permanent Link:

Relações

Em Collection:

Items

Miniatura Título Data de carga Acesso Ações
ScholarsDayPoster.pdf 2025-04-14 Público Baixar